Skip to main content
Equibles
ARQT logo

ARQT · Arcutis Biotherapeutics, Inc. · Metrics

Track ARQT — free

Use ARQT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARQT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$32.82 +0.93 (+2.92%) At close · Oct 20
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.09B
Shares
125.69M
Volume · Oct 20 4.49M Avg daily vol (3M) 2.4M

ARQT metrics

83 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$32.82
Market cap
$4.09B

Price action

20 metrics
Price change (1W)
+21.6%
Price change (30D)
+22.8%
Price change (3M)
+15.8%
Price change (6M)
+30.3%
Price change (YTD)
+9.8%
Price change (1Y)
+52.7%
Trailing year
Price change (5Y)
+45.1%
52-week high
$31.89
52-week low
$19.50
Change from 52-week high
+0.0%
Change from 52-week low
+63.5%
Annualized volatility
58.4%
Annualized volatility (3M)
55.6%
Beta
1.1
RSI (14D)
73.2
Price vs SMA 50
+24.5%
Price vs SMA 200
+27.1%
Avg volume (3M)
2.35M
Relative volume
2.5
Average dollar volume
$61.14M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
125.69M

Valuation

12 metrics
P / E (TTM)
145.0
Trailing earnings · reciprocal yield 0.7%
PEG ratio
—
EV / revenue
8.9×
reciprocal yield 11.2%
EV / EBITDA
—
EV / EBIT
120.9×
reciprocal yield 0.8%
P / sales
8.8×
reciprocal yield 11.4%
P / book
18.4
reciprocal yield 5.4%
FCF yield
1.0%
TTM · current market cap
Buyback yield
—
P / FCF
103.9
reciprocal yield 1.0%
P / operating cash flow
103.5
reciprocal yield 1.0%
Earnings yield
0.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
13.7×
reciprocal yield 7.3%
EV / revenue historical average (5Y)
24.0×
reciprocal yield 4.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
91.1%
Operating margin
7.4%
Trailing 12 months
Net margin
6.1%
Gross profit (TTM)
$422.88M
Operating profit (TTM)
$34.25M
Net income (TTM)
$28.52M
Trailing 12 months
Diluted EPS (TTM)
$0.22
FCF margin
8.4%
Effective tax rate
2.7%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.54

Growth

11 metrics
Revenue growth YoY
+59.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$463.98M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+7.0%
Year over year · more shares
Revenue CAGR (3Y)
+367.3%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
12.9%
Return on assets
5.8%
Debt / equity
0.5
Current ratio
2.9
EBITDA (TTM)
—
Free cash flow (TTM)
$39.15M
Quick ratio
2.7
Interest coverage
2.5
Net debt / EBITDA
—
Return on invested capital
11.3%
Trailing 12 months
Net cash
−$74.78M
Latest balance sheet
Cash & equivalents
$34.12M
Total assets
$488.54M
Total debt
$108.90M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$39.31M
Capital expenditures (TTM)
$158,000
R&D (TTM)
$91.04M
SG&A (TTM)
$297.60M
Stock compensation (TTM)
$43.55M
R&D / revenue
19.6%
Stock compensation / revenue
9.4%

Ownership (13F)

9 metrics
13F filers
272
13F filer change QoQ
+2
Institutional ownership
105.0%
Conviction holders (share of 13F filers)
1.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-2.8%
Holder tenure
14.6
Price vs estimated holder cost
+71.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.6%

Short interest

3 metrics
Short interest
17.3%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
88 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$2.18M
Insider-sentiment score
26 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1787306 CUSIP 03969K108 13F (30d) 29 filings 29 filers Visit website Investor relations